Mental health news and mental health widget

UCB announced today that Keppra XR offers convenient dosing for people with epilepsy. Keppra XR was approved by the U.S. Food and Drug Administration (FDA) in September 2008 for use as an add-on to other antiepileptic treatments for people with partial-onset seizures who are 16 years of age and older. While many people with epilepsy are successfully treated with one or more of the currently available antiepileptic drugs, a significant percentage still live with uncontrolled seizures or intolerable side effects. read more

The North Carolina Department of health and Human Services (DHHS) has settled litigation with a mental health services provider. The agreement calls for Dominion Healthcare to pay DHHS more than $1.6 million in reimbursements for disputed Medicaid payments.

Neuronetics, Inc. announced today that a new health economic study evaluating the cost effectiveness of its NeuroStar TMS Therapy system in the treatment of depression was presented at the U.S. Psychiatric and Mental Health Congress in San Diego last week. This study is the largest and most comprehensive cost effectiveness study to date of TMS Therapy in patients with major depression who have failed to achieve benefit from prior antidepressant treatment, also called treatment-resistant depression (TRD). read more